Skip Navigation

European Heart Journal 2004 25(4):283-284; doi:10.1016/j.ehj.2003.09.031
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kearney, M. T.
Right arrow Articles by Marber, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kearney, M. T.
Right arrow Articles by Marber, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Trends in incidence and prognosis of heart failure

You always pass failure on the way to success

Mark T. Kearneya and Michael Marberb,*

a Department of Cardiology GKT School of Medicine London, King's College Hospital London UK
b St Thomas's Hospital, London, UK

* Correspondence to: Michael Marber, Department of Cardiology, King's College London, The Rayne Institute, St Thomas's Hospital, London SE1 7EH, UK. Tel +44 20 9228191; fax +4420 9605659
E-mail address: mike.marber@kcl.ac.uk

Received 9 September 2003; accepted 25 September 2003

The first 10% of the full text of this article appears below.

This editorial refers to ''Decreasing one-year mortality and hospitalization rates for heart failure in Sweden by M. Schaufelberger et al. on page 300{dagger}

The last two decades of the 20th century saw a significant improvement in our understanding of the aetiology and pathophysiology of chronic heart failure (CHF), a disorder with a mortality rate higher than many soft tissue tumours.1Multiple neurohumoral pathways, abnormalities of cardiac shape, size and electrical activation, have been shown to influence the natural history of CHF. Based on this understanding, randomized controlled trials established angiotensin converting enzyme inhibitors, and more recently beta-adrenoceptor blockers and spironolactone, as agents that can improve the morbidity and mortality of CHF. On the way, we have also discovered those . . . [Full Text of this Article]

1. Do population studies suggest that we are successfully altering the natural history of chronic heart failure?

2. How valid are the data

3. Assessing prognosis in patients with heart failure

4. Perspective


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: Data from the Swedish Hospital Discharge Registry 1988 to 2000
Maria Schaufelberger, Karl Swedberg, Max Köster, Måns Rosén, and Annika Rosengren
EHJ 2004 25: 300-307. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, F. Follath, V.-P. Harjola, M. Hochadel, M. Komajda, J. Lassus, J. L. Lopez-Sendon, et al.
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population
Eur. Heart J., November 2, 2006; 27(22): 2725 - 2736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K.-M. Hermann-Arnhof, U. Hanusch-Enserer, T. Kaestenbauer, T. Publig, A. Dunky, H. R. Rosen, R. Prager, and U. Koller
N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure
Clin. Chem., January 1, 2005; 51(1): 138 - 143.
[Abstract] [Full Text] [PDF]